Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Non-Selective Beta-Blockers on Outcomes in Cirrhosis Patients After Hospitalization: A Retrospective Cohort Using Target Trial Design
Sponsor: Samsung Medical Center
Summary
The goal of this observational study is to learn if non-selective beta-blockers (NSBB) improve outcomes in patients with chronic hepatitis B or C who are discharged after hospitalization for acute decompensation of cirrhosis. The main questions it aims to answer are: 1. Does NSBB use at discharge reduce mortality rates in cirrhotic patients with hepatic complications? 2. Does NSBB use at discharge decrease hospital readmission rates? Researchers will compare patients discharged with NSBB prescriptions to those without NSBB to see if NSBB use decreases mortality and readmission rates. Participants were patients hospitalized for hepatic complications (hepatic encephalopathy, hepatorenal syndrome, ascites, or spontaneous peritonitis) between January 2013 and October 2023, with data analyzed retrospectively using a target trial emulation design.
Official title: Effect of Non-Selective Beta-Blockers on Outcomes in Patients Discharged After Hospitalization for Acute Decompensation of Cirrhosis: A Retrospective Cohort Study Using Target Trial Emulation Design
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
OBSERVATIONAL
Enrollment
7725
Start Date
2013-01-01
Completion Date
2025-12-31
Last Updated
2025-05-18
Healthy Volunteers
No
Interventions
Non-selective beta-blockers
Non-selective beta-blockers (NSBB) prescribed at discharge for patients hospitalized with hepatic complications. The study will analyze two types of NSBB: propranolol and carvedilol. The study will also examine potential dosage effects by categorizing NSBB use into low-dose and middle-high dose groups. NSBB use is defined as a prescription for at least 2 days at discharge.
Locations (1)
Samsung Medical Center
Seoul, South Korea